161 related articles for article (PubMed ID: 28458135)
1. Inhibitors of cytochrome P450 (CYP) 1B1.
Dutour R; Poirier D
Eur J Med Chem; 2017 Jul; 135():296-306. PubMed ID: 28458135
[TBL] [Abstract][Full Text] [Related]
2. Targeting cytochrome P450 (CYP) 1B1 with steroid derivatives.
Poirier D; Roy J; Cortés-Benítez F; Dutour R
Bioorg Med Chem Lett; 2016 Nov; 26(21):5272-5276. PubMed ID: 27687674
[TBL] [Abstract][Full Text] [Related]
3. Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
Lee D; Perez P; Jackson W; Chin T; Galbreath M; Fronczek FR; Isovitsch R; Iimoto DS
Bioorg Med Chem Lett; 2016 Jul; 26(14):3243-3247. PubMed ID: 27265259
[TBL] [Abstract][Full Text] [Related]
4. Targeting Cytochrome P450 (CYP) 1B1 Enzyme with Four Series of A-Ring Substituted Estrane Derivatives: Design, Synthesis, Inhibitory Activity, and Selectivity.
Dutour R; Roy J; Cortés-Benítez F; Maltais R; Poirier D
J Med Chem; 2018 Oct; 61(20):9229-9245. PubMed ID: 30216063
[TBL] [Abstract][Full Text] [Related]
5. Diaryl triazenes inhibit cytochrome P450 1A1 and 1B1 more strongly than aryl morpholino triazenes.
Moran R; Nakamura R; Isovitsch R; Iimoto D
Bioorg Med Chem Lett; 2022 Mar; 59():128570. PubMed ID: 35063631
[TBL] [Abstract][Full Text] [Related]
6. Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites.
Chang YP; Huang CC; Shen CC; Tsai KC; Ueng YF
Drug Metab Pharmacokinet; 2015 Oct; 30(5):374-83. PubMed ID: 26403084
[TBL] [Abstract][Full Text] [Related]
7. The Activation of Procarcinogens by CYP1A1/1B1 and Related Chemo-Preventive Agents: A Review.
Li Y; Cui J; Jia J
Curr Cancer Drug Targets; 2021; 21(1):21-54. PubMed ID: 33023449
[TBL] [Abstract][Full Text] [Related]
8. Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene.
Chun YJ; Oh YK; Kim BJ; Kim D; Kim SS; Choi HK; Kim MY
Toxicol Lett; 2009 Aug; 189(1):84-9. PubMed ID: 19463925
[TBL] [Abstract][Full Text] [Related]
9. Discovery of heterocycle-containing α-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors.
Dong J; Huang G; Cui Q; Meng Q; Li S; Cui J
Eur J Med Chem; 2021 Jan; 209():112895. PubMed ID: 33069055
[TBL] [Abstract][Full Text] [Related]
10. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance.
Sonawane VR; Siddique MUM; Gatchie L; Williams IS; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
Eur J Pharm Sci; 2019 Apr; 131():177-194. PubMed ID: 30776468
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons.
Shimada T; Guengerich FP
Chem Res Toxicol; 2006 Feb; 19(2):288-94. PubMed ID: 16485905
[TBL] [Abstract][Full Text] [Related]
12. The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer Cells.
Ruparelia KC; Zeka K; Ijaz T; Ankrett DN; Wilsher NE; Butler PC; Tan HL; Lodhi S; Bhambra AS; Potter GA; Arroo RRJ; Beresford KJM
Med Chem; 2018; 14(4):322-332. PubMed ID: 29332599
[TBL] [Abstract][Full Text] [Related]
13. Design of Cytochrome P450 1B1 Inhibitors
Hachey AC; Fenton AD; Heidary DK; Glazer EC
J Med Chem; 2023 Jan; 66(1):398-412. PubMed ID: 36520541
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human CYP1 enzymes by a classical inhibitor α-naphthoflavone and a novel inhibitor N-(3, 5-dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study.
Juvonen RO; Jokinen EM; Javaid A; Lehtonen M; Raunio H; Pentikäinen OT
Chem Biol Drug Des; 2020 May; 95(5):520-533. PubMed ID: 32060993
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity.
Hanna IH; Dawling S; Roodi N; Guengerich FP; Parl FF
Cancer Res; 2000 Jul; 60(13):3440-4. PubMed ID: 10910054
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationship studies of α-naphthoflavone derivatives as CYP1B1 inhibitors.
Dong J; Wang Z; Cui J; Meng Q; Li S
Eur J Med Chem; 2020 Feb; 187():111938. PubMed ID: 31830634
[TBL] [Abstract][Full Text] [Related]
17. α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship.
Chen P; Wang S; Cao C; Ye W; Wang M; Zhou C; Chen W; Zhang X; Zhang K; Zhou W
Bioorg Chem; 2021 Nov; 116():105295. PubMed ID: 34455300
[TBL] [Abstract][Full Text] [Related]
18. Design and Synthesis of New α-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression.
Cui J; Meng Q; Zhang X; Cui Q; Zhou W; Li S
J Med Chem; 2015 Apr; 58(8):3534-47. PubMed ID: 25799264
[TBL] [Abstract][Full Text] [Related]
19. Potential role of CYP1B1 in the development and treatment of metabolic diseases.
Li F; Zhu W; Gonzalez FJ
Pharmacol Ther; 2017 Oct; 178():18-30. PubMed ID: 28322972
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis and Binding Affinity Evaluation of Cytochrome P450 1B1 Targeted Chelators.
Chen D; Fan Q; Xu T; Dong J; Cui J; Wang Z; Wang J; Meng Q; Li S
Anticancer Agents Med Chem; 2022; 22(2):261-269. PubMed ID: 33820523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
